復星醫藥(600196.SH):控股子公司璀璨之星擬認購私募基金份額
格隆匯11月24日丨復星醫藥(600196.SH)公佈,2020年11月24日,公司控股子公司璀璨之星與Pontifax VI GP、Pontifax GP II Limited簽訂《Amended and Restated Exempted Limited Partnership Agreement of Pontifax (Cayman) VI L.P.》,璀璨之星擬作為有限合夥人出資4000萬美元認繳目標基金的等值份額。目標基金本次計劃募集總額1.48億美元,璀璨之星擬認繳份額約佔本次計劃募集總額的27.11%,實際持有的份額比例以目標基金最終募集完成情況為準。
同日,璀璨之星與Pontifax Management IV GP (2015) Ltd.、Tomer Kariv、Ran Nussbaum簽訂《Amended and Restated Limited Partnership Agreement of Pontifax VI GP L.P.》(以下簡稱“《執行事務合夥人合夥協議》”),璀璨之星作為有限合夥人出資101美元認繳目標基金執行事務合夥人Pontifax VI GP的等值份額,約佔Pontifax VI GP已募集總額的10.7%。
目標基金Pontifax(Cayman)VI L.P計劃募集總額1.48億美元(實際募集金額以最終募集完成情況為準),致力於在投資期內,投資於全球範圍內高成長性的生命科學公司,包括但不限於製藥、生物技術和醫療器械公司等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.